gregation, and activation of factors V and VIII [1]. Thrombin and more recently, factor Xa have been Diseases Boehringer Ingelheim Pharma KG intensively investigated as targets for antithrombotic therapy [2-7]. 88397 Biberach an der Riss Germany Recent preclinical and clinical studies with proteinaceous or small molecule agents have concentrated on selective inhibition of either of the two proteinases [8, 9]. In contrast, anticoagulant strategies of haematopha-Summary geous animals frequently involve multiple inhibition of the blood coagulation cascade and platelet activation Background: A major current focus of pharmaceutical research is the development of selective inhibitors of [10-14]. For instance, the soft tick Ornithodorus moubata prevents blood clotting through direct inhibition the blood coagulation enzymes thrombin or factor Xa to be used as orally bioavailable anticoagulant drugs of thrombin by ornithodorin [15], of factor Xa by tick anticoagulant peptide (TAP) [16-18] and inhibition of in thromboembolic disorders and in the prevention of venous and arterial thrombosis. Simultaneous direct in-platelet aggregation by moubatin [19, 20]. Other notorious examples of blood sucking organisms with similar hibition of thrombin and factor Xa by synthetic proteinase inhibitors as a novel approach to antithrombotic strategies are the medicinal leech Hirudo medicinalis [21] and the Mexican leech Haementeria officinalis therapy could result in potent anticoagulants with improved pharmacological properties. [22, 23]. The targeting of several enzymes active within the same physiological pathway therefore appears to be an Results: The binding mode of such dual specific inhibitors of thrombin and factor Xa was determined for the evolutionarily favored strategy. Moreover, heparin, a currently widely used anticoagu-first time by comparative crystallography using human ␣-thrombin, human des-Gla (1-44) factor Xa and bovine lant, inhibits both thrombin and factor Xa indirectly via complex formation with and modulation of the activity trypsin as the ligand receptors. The benzamidine-based inhibitors utilize two different conformations for the in-of the serine proteinase inhibitor (serpin) antithrombin III (for review see [24]). This therapy suffers from a num-teraction with thrombin and factor Xa/trypsin, which are evoked by the steric requirements of the topologically ber of weaknesses, e.g., lack of oral bioavailability, side effects such as thrombocytopenia, and the necessity of different S2 subsites of the enzymes. Compared to the unliganded forms of the proteinases, ligand binding in-intensive clinical monitoring, most of which are associated with the chemical nature of heparin itself. duces conformational adjustments of thrombin and factor Xa active site residues indicative of a pronounced A combination of thrombin and factor Xa inhibitory activity in a single, synthetic, orally bioavailable, small induced fit mechanism. molecular weight compound as a novel approach to antithrombotic therapy should therefore result in potent Conclusion: The structural data reveal the molecular basis for a desired unselective inhibition of the two key anticoagulants with potentially superior features over currently available therapies. components of the blood coagulation cascade. The 4-(1methyl-benzimidazole-2-yl)-methylamino-benzamidine Thrombin and factor Xa belong to the trypsin family of serine proteinases. Structural data for thrombin [25, moieties of the inhibitors are able to fill both the small solvent accessible as well as the larger hydrophobic S2 26], factor Xa [27], and trypsin [28] show strong similarities of the S1 specificity pockets of the three enzymes. pockets of factor Xa and thrombin, respectively. Distal fragments of the inhibitors are identified which fit into The S2 and S4 subsites show distinct topologies. While S2 is covered by the 60 insertion loop (the sequence both the cation hole/aromatic box of factor Xa and the hydrophobic aryl binding site of thrombin. Thus, binding nomenclature used is based on the topological equivalences of the discussed enzymes with chymotrypsino-constants in the medium-to-low nanomolar range are obtained against both enzymes. gen [29] and on the thrombin nomenclature suggested by Bode et al. [30]) in thrombin and is hydrophobic in nature, it is smaller and solvent accessible in factor Xa Introduction and trypsin. The aryl binding site of thrombin above the conserved residue Trp-215 is lined by residues Leu-99 Activation of the extrinsic or intrinsic pathways of the coagulation cascade leads to the conversion of the zy-and Ile-174. In factor Xa, this subsite is built by the
crystal structures of active site inhibited factor Xa have been solved and refined at low or medium resolution and published [31, 34, 35] .
We have determined crystal structures of two related synthetic inhibitors, BIBT0871 and BIBR1109 (Figure 1 ), in complex with their target proteinases, human ␣-thrombin and human des-Gla (1-44) factor Xa, as well as their complexes with bovine trypsin.
The crystal structure analyses were carried out at 1.9-2.0 Å resolution (with the exception of the FXa-BIBR1109 complex at 3.0 Å ) resulting in high quality structures with the expected low residual errors for atomic positions channels in the crystals and is therefore disordered.
General Binding Mode of the Inhibitors corresponding residues Tyr-99 and Phe-174, which to-
The inhibitors are benzamidine-based compounds that gether with the indole ring system of Trp-215 form the bind to the specificity pocket of all three enzymes in a walls of an aromatic box. In the back of this pocket, similar way and form the expected twin-twin interaction amide carbonyl groups from the backbone around resiof their amidine moiety with the side chain of Asp-189 due 99 form a distinct pattern of hydrogen bond acat the bottom of the S1 subsite. The distal substituents ceptors in both enzymes with the thrombin 99-loop beof the inhibitors are aromatic ring systems that were ing one residue longer than in factor Xa. In the latter designed to fit into the aryl binding sites of thrombin enzyme, the 99-loop carbonyls and the side chain of and factor Xa. There is a N-methyl-benzimidazole scaf-E97 form the so-called cation hole and favor occupation fold that bridges the benzamidine and the distal aroof the aromatic box by basic groups such as amidines matic rings that is positioned above the peptide backor other positively charged substituents [31] .
bone of residues 214-216 and is not able to form the Based on the assumption that simultaneous inhibition canonical hydrogen bonds with it. of the two key components of the blood coagulation cascade would be therapeutically advantageous and based on the presence of a fair structural similarity of Factor Xa -BIBT0871 Complex the active sites of the two proteinases, we started a The exocyclic torsion angles within the diatomic bridge medicinal chemistry program concerned with the search connecting the benzamidine and benzimidazole ring for potent, orally bioavailable, dual specific inhibitors of systems (at the aniline nitrogen Ϫ17Њ, at the carbon atom thrombin and factor Xa. 101Њ) suggest that the inhibitor is bound in a low energy In our design of these inhibitors, we used 4-(1-methylconformation ( Figure 3 ). As a result, the N-H vector is benzimidazole-2-yl)-methylamino-benzamidine as the pointing toward the side chain of Ser-195 forming a basic scaffold (Figure 1 ). This molecular fragment turns hydrogen bond interaction with the serine hydroxyl out to be ideally suited to meet the steric requirements group. The 1-methyl-benzimidazole scaffold lies flat on for fitting equally well into the S1 and S2 pockets of the protein surface above Gly-216 and places the methyl thrombin and factor Xa. The exploration of distal substitsubstituent into the S2-subsite. The S4-subsite of factor uents on the inhibitor scaffold fitting into the S4 subsites Xa is occupied by the pyridinyl moiety of BIBT0871, of both enzymes generated molecules that simultanewhich is positioned such that it forms an aromatic stackously inhibit very efficiently both thrombin and factor ing interaction with Phe-174 (ring distance 3.6 Å ) and Xa. The most potent example of this series, BIBM1015, an edge-on interaction with Trp-215 (distance 3.8 Å ). exhibits inhibition constants in the low nanomolar range.
The structure of the enzyme active site is changed Here, we describe, for the first time in a comparative slightly concomittant to inhibitor ligation, suggesting an fashion, the binding mode of two inhibitors of this familiy induced fit type binding mechanism. The factor Xa S1in thrombin, factor Xa and trypsin. As it turns out, the subsite in the BIBT0871 complex is narrower compared molecules bind in two distinct conformations to thromto that of the self-complexed form of factor Xa, which, bin and factor Xa/trypsin, respectively. The crystal strucin the particular tetragonal crystal form described [27] , tures explain the structural cause for the dual inhibition is filled with the C-terminal arginine residue of the EGF2 properties and experimentally verify that trypsin may domain of a neighboring, symmetry equivalent moleserve as a potent active site surrogate for factor Xa as cule. However, a comparison with the other inhibitor previously suggested [32] .
bound structures of factor Xa [31, 34] reveals that the narrow S1-subsite circumference is probably the relaxed conformation and that the rigid body motion of Results residues 190-194 around the oxyanion hole may be induced by the particular interaction with the EGF2 C-ter-While for thrombin and trypsin an abundance of cocrystal structures have been reported [33] , to date only few minal peptide chain in the self-complexed form [27] . To create space for the N-methyl group and the ben-avoid sterically unfavorable contacts. The His-57 side chain is shifted by 
the absence of Tyr-99 (which is Leu-99 in trypsin) and
The bound conformations of the inhibitors are identical in factor Xa and trypsin but distinct from the binding because the aryl binding site is not confined by spacious residues but rather flat and solvent accessible. mode utilized when the inhibitors bind to thrombin (Figure 6) .
While the active site of trypsin is rather flat in the S2-Discussion and S4-subsite areas and allows for a relaxed bound inhibitor conformation, the clefts of thrombin and factor Two inhibitors with a mixed inhibition profile toward the Xa are rather deep and impose severe restrictions on blood coagulation proteinases thrombin and factor Xa the available space to be occupied by the inhibitor. were cocrystallized with the proteinases thrombin, fac-Thus, to occupy the proximal S2-pocket of thrombin tor Xa, and trypsin. with its N-methyl-benzimidazole group while main-The inhibitor structures allow for efficient occupation
taining the favorable ionic interactions in the specificity of the S1-and S4-subsites of the enzymes, however, pocket, the inhibitor has to adopt the observed thrombin functional groups for the formation of the canonical bound conformation which places the NH group into hydrogen bonding interactions observed for peptide debulk solvent without the possibility of forming a hydrorived inhibitors [25, 38] are absent. In contrast to pubgen bond with Ser-195 OH. This conformation of the lished factor Xa specific inhibitors [31] , the 1-methylproximal inhibitor fragment in turn, however, allows an benzimidazole moiety provides a methyl group for the optimal occupation of the distal aryl binding site. occupation of the small S2-subsite of this proteinase, In factor Xa, the main restriction imposed on the inhibiwhich predominantly cleaves peptide sequences with glycine at P2 [1, 39, 40] .
tor is the maintenance of the S1-subsite interaction of the benzamidine with the Asp-189 carboxylate and fur-ent from the thrombin case, but seems equally well suited for optimal occupation of this site. ther to put the methyl substituent of the benzimidazole into the S2-subsite as a P2 surrogate. This is possible Inhibition constants toward thrombin and factor Xa for the two cocrystallized inhibitors are reported in Table  while maintaining 
Figure 5. Comparison of the Inhibitor Conformations as Bound to Factor Xa and Trypsin

Stereo representation of BIBR1109 (green carbon atoms) in complex with trypsin (gray carbon atoms) and superimposed on the active site structure of BIBR1109 (magenta carbon atoms) in complex with factor Xa (orange carbon atoms). The inhibitor conformations are identical between the two structures.
observed selectivity of the inhibitors toward the fibrino-methylamino-benzamidine moiety, the binding mode of this compound to factor Xa and thrombin is identical lytic enzymes (plasmin, urokinase, and tPA) of 2-3 orders of magnitude may be sufficient for excluding any to the described binding modes of BIBR1109 and BIBT0871 as shown by its cocrystal structures with effect compromising their anticoagulant activity in vivo.
The lack of selectivity toward trypsin, present in the thrombin and trypsin (data not shown). BIBM1015 exhibits Ki values of 15 nM for factor Xa and 20 nM for throm-gastrointestinal duct, is anticipated to be of no concern for the following reason. The strong hydrophilic charac-bin and represents one of the most potent dual inhibitors reported to date. It serves as a starting point for an ter of the compounds results in low oral bioavailabilities of the presented compounds (data not shown). How-optimization program for combined factor Xa/thrombin inhibitors in our group. ever, modification of the active principle to a prodrug form by chemical masking of the charged groups pro-The comparative analysis of 3D structures of inhibitors bound to thrombin, factor Xa and trypsin further deep-duces biologically inactive molecules that are resorbed after oral administration. The prodrugs will not interfere ens the understanding of the scope and limitations of the active site surrogate approach for trypsin-like pro-with the trypsin activity in the gastrointestinal duct, but are converted to the active compounds by enzymes teinases using trypsin cocrystal structures. They show that for the presented and similar types of synthetic present in the gastrointestinal wall, blood, or liver.
The factor Xa inhibition was determined to be about inhibitors, trypsin may indeed be used as an active site model for factor Xa, but it may not yield relevant results 3-to 15-fold more efficient relative to thrombin inhibition. In the light of the described structures, the potency for the thrombin bound conformations. The present work shows that inhibitors exhibiting a against factor Xa is in part based on a favorable solvent shielded NH-O␥ Ser-195 interaction. This is in line with mixed activity profile toward thrombin and factor Xa utilize different binding conformations albeit similar mo-the observed structure activity relationships for other classes of substituted benzamidines with hydrogen lecular interactions with the proteinases. By elucidating these distinct binding modes of identical inhibitors as bond donors in the para-position [41] . The potency against thrombin, in contrast, is based mainly on a large being bound to the two enzymes, most useful information is obtained for the design of a new generation of area of buried hydrophobic surface with the 1-methylbenzimidazole fitting snugly into the S2-pocket of the potent antithrombotic drugs directed against the two key proteinases of the blood coagulation cascade. enzyme.
In a search for more potent inhibitors of this family, we were able to identify a suitable substitution of the Biological Implications aromatic residues binding to the S4-pockets of thrombin and factor Xa by a sterically less demanding pyrrolidine
The search for potent orally bioavailable anticoagulants as effective drugs in thromboembolic disorders such as amide as realized in BIBM1015 (Figure 1 and Table 2 ). Due to the conserved 4-(1-methyl-benzimidazole-2-yl)-deep vein thrombosis and in the prevention of venous indirect action on thrombin and factor Xa via the serpin antithrombin III. Fourth, a potent direct dual specific A combination of the effects of thrombin and factor Xa inhibitors as a novel approach to the therapy of inhibitor may be therapeutically effective at lower plasma concentrations compared to selective inhibitors. Finally, thromboembolic disorders appears to be an attractive goal in antithrombotic research for various reasons. a compound that combines two modes of action in a single chemical entity carries additional advantages First, blood sucking animals have developed strategies to prevent blood clotting by simultaneous inhibition of over the combination of separate compounds by facilitating clinical testing and registratory matters. two or more procoagulatory factors suggesting that mimicking such an evolutionarily developed approach
The search for anticoagulant drugs has been efficiently guided by the knowledge derived from known by the invention of synthetic agents with a similar inhibition profile may be similarly successful in therapeutic 3D structures of the targeted serine proteinases. Based on the similarity of the active site structures of thrombin applications. Second, several effective therapeutic approaches, such as the treatments of HIV (protease and and factor Xa and based on the above reasoning, we have set out to explore whether it is possible to design reverse transcriptase inhibitors) [42] , hypertension [43], Data are the Ki mean values and standard deviations (in parentheses) calculated from 12 independent determinations for the target enzymes factor Xa, thrombin and trypsin (6 for the selectivity data against the bottom 5 proteases). 
zymes.
Here, we describe the crystal structures of two inhibi- shows how a particular inhibitor is able to inhibit two distinct albeit related enzymes using two different con-
